Nightingale Health joins South Savo Wellbeing Services County's preventive healthcare research project in Finland

Nightingale Health Plc | Press Release | May 28, 2026 at 11:00:00 EEST

Nightingale Health is participating in the Wellbeing Gift (Hyvinvointilahja) project launched by Eloisa, the Wellbeing Services County of South Savo, in which blood-based disease risk detection is combined with digital lifestyle support. Through the project, residents of the Wellbeing Services County aged 45, 50, and 55 are offered a free preventive health assessment and participants identified at elevated risk are directed to targeted digital lifestyle support. The scientific evaluation of the project is led by the University of Eastern Finland, and the project runs from March 2026 to April 2027.

Nightingale Health's contribution to the project is the blood-based disease risk detection. From a single blood sample, Nightingale Health’s test produces an individual risk estimate for five common chronic diseases: heart attack, ischemic stroke, type 2 diabetes, chronic kidney disease, and fatty liver disease. Participants receive their results in a personal report, and those identified at elevated risk are directed to a remote consultation with an Eloisa nurse and to digital lifestyle support. Clinical follow-up is delivered within Eloisa's existing care pathways.

The Wellbeing Gift project is the first practical step in the collaboration that Nightingale Health and the South Savo Wellbeing Services County announced on June 16, 2025. At that time, the parties announced an agreement to apply Nightingale Health's disease risk detection technology as part of the wellbeing services county's primary healthcare. In the Wellbeing Gift project, the operating model and its impact are evaluated before a possible broader rollout.

Nightingale Health's technology is already in nationwide healthcare use in Finland through occupational healthcare, and over 200,000 people have received their Nightingale Health Check results. Through the Wellbeing Gift project, the same approach is now applied within a wellbeing services county's operating environment. The project aims to generate research evidence on how targeted digital lifestyle support helps prevent lifestyle-related chronic diseases, and to develop a scalable model that can be applied more broadly across other wellbeing services counties.

"Finland has a long tradition of developing preventive healthcare, and the project we are carrying out with Eloisa continues that work in a new way. The ability to detect disease risks in an individual from a blood sample gives healthcare a way to target support to those who benefit most, before disease develops. Through the Wellbeing Gift project, this approach becomes part of a wellbeing services county's operating model, while at the same time generating research evidence on how prevention affects the effectiveness of healthcare and people's wellbeing over the long term," says Teemu Suna, CEO and Founder of Nightingale Health.

The Wellbeing Gift project is implemented by Eloisa together with its partner network. The project is funded by Sitra, the Finnish Innovation Fund operating under the supervision of the Finnish Parliament, and by Eloisa. Other partners are the University of Eastern Finland, ISLAB, Vertical, Onnikka and BitHabit. More information on the project's structure, eligibility criteria, and registration is available in Eloisa's own press release and at www.etelasavonha.fi/hyvinvointilahja.

About Nightingale Health
Chronic diseases cause around 75% of deaths globally and place a growing burden on healthcare systems. The way to address this is preventive healthcare, but until recently the tools to detect disease risks at population scale have not existed. Nightingale Health has built them. The Nightingale Health Check is a blood-based risk detection test that identifies risks for multiple chronic diseases, including cardiovascular disease, type 2 diabetes, kidney disease, and fatty liver disease, from a single blood sample. It is designed to be applied population-wide, so healthcare systems can identify the people who would benefit most from preventive action before disease develops.

Nightingale Health's technology is validated in over 900 peer-reviewed scientific publications and is used in many of the world's leading health studies, including the UK Biobank. In Finland, the Nightingale Health Check is in nationwide healthcare use, and over 200,000 people have already received their results. Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, and has customers in more than 34 countries across healthcare and medical research. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/